# US 2022/0031672 A1 · Discovery of novel anti-infectives for gram negative pathogens

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031672 A1
- Document ID: US20220031672A1
- Status: Published application
- Kind: A1
- Application number: 17/279,015
- Filed: 2019-10-04
- Published: 2022-02-03
- Earliest claimed: 2018-10-04
- Assignees: The Regents of the University of California
- Applicants: The Regents of the University of California
- Inventors: Philip Bulterys; Jeffery F. Miller; Robert D. Damoiseaux; Christopher Todd French
- Web page: https://patentgrep.com/patent/US20220031672A1

## CPC

- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61P 31/04: Antibacterial agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Burkholderia pseudomallei (Bp) and Burkholderia mallei (Bm) are Tier-1 select pathogens that cause highly lethal human infections with limited therapeutic options. Intercellular spread is a hallmark of Burkholderia pathogenesis and its prominent ties to virulence make it an attractive therapeutic target. We developed a high-throughput cell-based phenotypic assay and screened ˜220,000 small molecules for their ability to disrupt intercellular spread by Burkholderia thailandensis, a BSL-2 surrogate for these pathogens. 268 hits were identified, and cross-species validation found 32 hits that also disrupt intercellular spread by Bp and/or Bm. In a fulminant murine model of respiratory melioidosis, treatment with a number of these agents was significantly more effective than ceftazidime, the current drug of choice, for improving patient survival and decreasing bacterial counts in major organs.

## Claims

### Claim 1

A method of inhibiting intercellular spreading of Burkholderia pseudomallei or Burkholderia mallei bacteria, the method comprising contacting the Burkholderia pseudomallei or Burkholderia mallei bacteria with at least one agent shown in FIG. 8;
wherein the Burkholderia pseudomallei or Burkholderia mallei bacteria are contacted with amounts of agent(s) sufficient to inhibit intercellular spreading of the Burkholderia pseudomallei or Burkholderia mallei bacteria.

### Claim 2 (depends on 1)

The method of claim 1, wherein Burkholderia pseudomallei or Burkholderia mallei bacteria are contacted with a fluoroquinolone and/or an agent comprising a morpholine moiety shown in FIG. 8.

### Claim 3 (depends on 1)

The method of claim 1, wherein the agent is a prodrug that is converted by Burkholderia pseudomallei or Burkholderia mallei into an agent having activity against said bacteria.

### Claim 4 (depends on 1)

The method of claim 1, wherein the agent is disposed within a composition further comprising a pharmaceutically acceptable carrier selected from at least one of: a pH adjusting agent, a buffering agent, a tonicity adjusting agent, a wetting agent, an antioxidant, a viscosity-increasing agent or a preservative.

### Claim 5 (depends on 4)

The method of claim 4, wherein the agent is contacted with the Burkholderia pseudomallei or Burkholderia mallei bacteria growing in vivo.

### Claim 6 (depends on 5)

The method of claim 5, wherein the the agent is administered to a patient diagnosed with melioidosis or glanders disease.

### Claim 7 (depends on 6)

The method of claim 6, wherein:
the patient is administered the agent at doses between 1 mg/kg/day and 250 mg/kg/day; and/or
agent is administered to the patient at least 1, 2 or 3 times/day for at least 4, 5, 6, or 7 days.

### Claim 8 (depends on 1)

The method of claim 1, wherein concentrations of at least 1 μM or 5 μM or 10 μM of the agent comprises amounts of agent(s) sufficient to inhibit intercellular spreading of the Burkholderia pseudomallei or Burkholderia mallei bacteria.

### Claim 9 (depends on 1)

The method of claim 1, wherein the agent inhibits intercellular spreading of Burkholderia pseudomallei or Burkholderia mallei bacteria to an extent greater than that observed with ceftazidime at concentrations of 0.125 μM to 8 μM.

### Claim 10

A composition of matter comprising at least one agent shown in FIG. 8.

### Claim 11 (depends on 10)

The composition of claim 10, wherein the composition further comprises a pharmaceutically acceptable carrier selected from at least one of: a pH adjusting agent, a buffering agent, a tonicity adjusting agent, a wetting agent, an antioxidant, a viscosity-increasing agent or a preservative.

### Claim 12 (depends on 10)

The composition of claim 10, wherein the agent comprises a fluoroquinolone and/or a morpholine group.

### Claim 13 (depends on 10)

The composition of claim 10, wherein the agent the agent is a prodrug that is converted by Burkholderia pseudomallei or Burkholderia mallei into an agent having activity against said bacteria.

### Claim 14 (depends on 10)

The composition of claim 10, further comprising at least one additional agent selected for its ability to inhibit growth of Burkholderia pseudomallei and/or Burkholderia mallei bacteria.

### Claim 15 (depends on 14)

The composition of claim 14, wherein the additional agent comprises a Flucytosine; a Trimethoprim; a Levofloxacin; a Flumequine; a Sulfamethoxazole; a Gatifloxacin; a Perfloxacin; an Oxolinic acid; a Monensin; a Ceftazidime; a carbapenem; an amoxicillin-clavulanic acid or an Artemisinin.

### Claim 16 (depends on 10)

The composition of claim 10, further comprising an excipient selected to facilitate parenteral administration to a patient diagnosed with melioidosis or glanders disease.

### Claim 17

A method of identifying agents capable of disrupting intercellular spread of Burkholderia species; the method comprising:
placing mammalian cells infected with Burkholderia thailandensis bacteria that are actively replicating and spreading in the mammalian cells into a plurality of containers;
placing a plurality of test agents into the plurality of containers so that one agent is present in one container;
allowing the Burkholderia thailandensis bacteria to grow for a period of time;
imaging the relative abundance and size of bacterial plaques in the plurality of containers; and
identifying agents that inhibit plaque formation; such that agents capable of disrupting intercellular spread of Burkholderia species are identified.

### Claim 18 (depends on 17)

The method of claim 17, wherein the mammalian cells are eGFP-expressing HEK293 cells.

### Claim 19 (depends on 17)

The method of claim 17, wherein the plurality of containers are pinned with a library of potential inhibitors.

### Claim 20 (depends on 17)

The method of claim 17, further comprising examining the ability of an agent identified as inhibiting Burkholderia thailandensis intercellular spreading to inhibit intercellular spreading of Burkholderia pseudomallei and/or Burkholderia mallei.
